Non-small cell lung carcinoma (NSCLC) therapy has been transformed by the identification of actionable oncogenic driver mutations, of which ALK, ROS1, RET fusions and MET exon 14 skipping represent interesting drug targets [1]. Here, ALK is linked to non-small cell lung carcinoma.